TY  - JOUR
T1  - Akromegali
TT  - Acromegaly
AU  - Uçan, Bekir
AU  - Demirci, Taner
PY  - 2019
DA  - April
DO  - 10.32322/jhsm.485584
JF  - Journal of Health Sciences and Medicine
JO  - J Health Sci Med /JHSM /jhsm
PB  - MediHealth Academy Yayıncılık
WT  - DergiPark
SN  - 2636-8579
SP  - 62
EP  - 67
VL  - 2
IS  - 2
LA  - tr
AB  - Akromegaliaşırı büyüme hormonu (BH) salınımısonucu ortaya çıkan klinik sendromdur. Akromegalinin en sık nedeni ön hipofizdeBH salgılayan adenomdur. Akromegali başlangıcı sinsi ve genellikle yavaşseyirlidir. Hemen hemen tüm hastalarda akral kemik ve yumuşak dokularda aşırıbüyüme mevcuttur. Karakteristik bulgular alt çene çıkıklığı, el ve ayak büyümesidir.Akromegali hastalarında kardiyovasküler hastalık, kolon kanseri, tiroid kanserive diğer tümörlerde risk artışı görülmektedir. Ölüm genellikle kardiyovaskülerhastalıklar nedeniyle olmaktadır. Akromegalinin temel tedavisi transsfenoidalcerrahidir. Cerrahi sonrası kür sağlanmazsa uzun etkili somatostatinanalogları, kabergolin, pegvisomant gibi medikal tedaviler kullanılır. Medikaltedaviye rağmen BH/IGF-1 veya adenom boyutunda artış olursa reoperasyon veya radyoterapikullanılabilir.
KW  - Akromegali
KW  - tanı
KW  - tedavi
N2  - Acromegalyis the clinical syndrome that results from excessive secretion of growthhormone (GH). The most common cause of acromegaly is a GH secreting adenoma ofthe anterior pituitary. The onset of acromegaly is insidious, and itsprogression is usually very slow. Nearly all patients with acromegaly haveacral osseous and soft tissue overgrowth. The characteristic findings are anenlarged jaw and enlarged, swollen hands and feet. Patients with acromegalyappear to be at increased risk for cadiovascular disase, colon cancer, thyroidcancer and other tumors. Death is generally caused by cardiovascular diseases. Transsphenoidalsurgery is the main therapy for patients with an acromegaly. After surgicalfailure long-acting somatostatin analog, cabergolin or pegvisomant areindicated. If adenoma size increases or GH/IGF-1hypersecretion persists despite medical therapy, we suggest radiation therapy(RT) or repeat surgery.
CR  - 1.	Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.2.	Ribeiro-Oliveira A jr, Barkan A. The changing face of acromegaly-advances in diagnosis and treatment. Nat Rev Endocrinol 2012; 8:605.3.	Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119:3189.4.	David G. Gardner, Dolores Shoback. Greenspan's Basic and Clinical Endocrinology. Tenth Edition. McGraw-Hill Education; 2017.5.	Yashpal Gogate , Anil Bhansali. Clinical rounds in endocrinology: Volume I – adult endocrinology.  Springer, India. 1st ed. 2016.6.	Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933.7.	Shlomo Melmed, Laurence Katznelson. Acromegaly. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on Jan 18, 2018.)8.	Biermasz NR. New medical therapies on the horizon: oral octreotide. Pituitary. 2017 Feb;20(1):149-153.9.	Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A. Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother. 2016 Aug;17(12):1631-42.10.	Grynberg M, Salenave S, Young J, Chanson P.  Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab. 2010;95(10):4518.
UR  - https://doi.org/10.32322/jhsm.485584
L1  - http://dergipark.org.tr/tr/download/article-file/689740
ER  -